Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|ADVL1121||COG||A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma; Wilms Tumor; Hepatocellular Carcinoma; and Papillary Thyroid Carcinoma||Pediatric CIRB||Completed|
|ACCL0934||COG||A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Groupwide Phase III Study||Pediatric CIRB||Completed|
|S0226||SWOG||Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-38||NSABP||A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)||Adult CIRB - Late Phase Emphasis||Completed|
|AREN0321||COG||Treatment of High Risk Renal Tumors: A Groupwide Phase II Study||Pediatric CIRB||Completed|
|ACNS0232||COG||Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma: A Phase III Group-Wide Study||Pediatric CIRB||Completed|
|AAML05P1||COG||Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Stem Cell Transplantation (SCT) for AML with Monosomy 7; -5/5q-; High FLT3-ITD AR; or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncology Group (COG) Study (A Groupwide Pilot Study)||Pediatric CIRB||Completed|
|GOG-0250||GOG||A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297||Adult CIRB - Late Phase Emphasis||Completed|
|S0518||SWOG||Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced; Poor Prognosis Carcinoid Patients||Adult CIRB - Late Phase Emphasis||Completed|
|ADVL0221||COG||A Phase II Study of Trabectedin (ET-743; Yondelis) in Children with Recurrent Rhabdomyosarcoma; Ewing Sarcoma; or Nonrhabdomyosarcomatous Soft Tissue Sarcomas||Pediatric CIRB||Completed|